Taken together, these findings suggest that genetic deficiency or pharmacological inhibition of COX-2 significantly reduces stroke-induced neurovascular injury possibly by reducing MMP-9-mediated proteolysis of BBB structural components. This evidence concerns the gene MMP9 and Stroke.